
Cardionovum has announced that the APERTO 600 study, evaluating the efficacy of the Aperto over-the-wire (OTW) drug-coated balloon (DCB) in vascular access occlusion management, has been published in the Journal of Vascular Access.
APERTO 600 is a single-centre, retrospective cohort study analysing 600 DCB angioplasties performed in patients with stenoses or thromboses in arteriovenous fistulas (AVFs), vascular access grafts (AVGs), and central veins (CVS).
The study confirmed the excellent performance of Aperto OTW DCB, reporting overall functional patency rates of 80%, 63%, and 47% at 12, 24, and 36 months, respectively. Freedom from restenosis at 12 months was 71% for AVFs, 64% for AVGs, and 57% for central vein stenoses.
Notably, the annual re-intervention rate was 1.3 (IQR: 0.9–3.1), with no major adverse events or vascular injuries reported.
Matteo Tozzi (University of Insubria, Varese, Italy), principal Investigator of the study, stated: “Aperto OTW DCB is a safe and effective treatment for vascular access stenoses, demonstrating robust functional patency and low restenosis rates. Our findings support its use as a cornerstone in vascular access management, highlighting its role in reducing complications and maintaining long-term access functionality.”